Quoin Files $150M Universal Shelf While Carrying Going-Concern Doubt
QNRX sits 23% above its 52-week low of $3.25.
Summary
Quoin registered a $150 million universal shelf covering ADSs, warrants, rights, debt and units, giving it capacity for future raises. No securities were sold; the I.B.6 float limit caps near-term primary issuance at roughly one-third of its ~$36.4 million public float.
Key Events · Financing and Capital Events · QNRX
-
Universal Shelf Registered
Form S-3 covers up to $150,000,000 of ordinary shares represented by ADSs, warrants, subscription rights, debt securities and units, sellable from time to time after effectiveness.
-
Float Cap Limits Near-Term Sales
Public float was approximately $36,422,384 as of October 23, 2026; under General Instruction I.B.6, primary sales are capped at one-third of float in any 12-month period while float stays below $75.0 million — roughly $12.1M of capacity (36,422,384 / 3).
-
Going-Concern Backdrop
The Q2 2026 10-Q filed August 14, 2026 reiterated going-concern doubt, making this shelf the likely vehicle for the next capital raise.
-
Share Count and Headroom
5,000,000,000 ordinary shares authorized versus 168,145,635 outstanding as of October 23, 2026, with each ADS representing 35 ordinary shares — authorization is not the constraint on dilution.
Analysis · QNRX · Life Sciences
Quoin now has permission to sell up to $150 million of stock, warrants, rights, debt or units from time to time — but nothing has been sold. The practical constraint is much tighter than the headline: because public float is roughly $36.4 million, General Instruction I.B.6 caps primary sales at one-third of float in any 12-month window, so near-term issuance capacity is on the order of $12 million unless the float rises above $75 million. Against a Q2 10-Q that reiterated going-concern doubt, this shelf is the mechanism for the next raise, and each tranche will arrive as a 424B supplement with real dilution. The company also has 5.0 billion ordinary shares authorized versus 168.1 million outstanding, so share-count headroom is not the binding constraint — pricing and demand are.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNRX was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $3.25 to $23.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.